New Biopsy Technique for Uveal Melanoma

NCT ID: NCT01924923

Last Updated: 2015-03-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-06-30

Study Completion Date

2015-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This pilot study intends to investigate a new biopsy technique that will decrease the incidence of tumor cells in the biopsy tract.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Uveal melanoma is the most common primary malignancy of the eye and is one of the few fatal diseases that are detected initially through an eye examination. For many years, clinical decision-making regarding which patient with uveal melanoma required treatment has been based solely on clinical features observed at the time of diagnosis. These features include: tumor size as measured by ultrasound, associated subretinal fluid, presence of orange lipofuscin pigment, lack of drusen, posterior location, and ciliary body involvement. All of these clinical features have been demonstrated to be associated with tumor growth which is associated with the eventual development of metastases. However, these clinical features are not adequately sensitive or specific enough to predict which patients will develop metastases.

More recently, researchers studying the genomics of uveal melanoma have focused on identifying genetic abnormalities present in tumor tissue in order to characterize these lesions more fully. Several landmark papers over the past 15 years have reported cytogenic and genomic abnormalities in uveal melanoma tumor tissue that are associated with a poorer prognosis. Although rare, there have been at least five cases in which patients undergoing biopsy of these lesions have developed extraocular spread of melanoma from the biopsy sites. With this new technique, the possible rate of extraocular spread should be lower, making the biopsy a safer technique than what is currently in practice.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Uveal Melanoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Uveal Melanoma

Scheduled for enucleation surgery

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed with uveal melanoma
* Scheduled for enucleation surgery

Exclusion Criteria

* Patients under 21 years old
* Patients unable to undergo surgery
* Patients with known metastatic uveal melanoma or other cancer.
Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Methodist Hospital Research Institute

OTHER

Sponsor Role collaborator

Greater Houston Retina Research

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Amy C Schefler, MD

Director of Ophthalmic Oncology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Amy C. Schefler, MD

Role: PRINCIPAL_INVESTIGATOR

Retina Consultants Houston

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Retina Consultants of Houston

Houston, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma III: local complications and observations following enucleation COMS report no. 11. Am J Ophthalmol. 1998 Sep;126(3):362-72. doi: 10.1016/s0002-9394(98)00091-9.

Reference Type BACKGROUND
PMID: 9744369 (View on PubMed)

The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma II: initial mortality findings. COMS report no. 10. Am J Ophthalmol. 1998 Jun;125(6):779-96. doi: 10.1016/s0002-9394(98)00039-7.

Reference Type BACKGROUND
PMID: 9645716 (View on PubMed)

Schyberg E. Fine needle biopsy of orbital tumours [proceedings]. Acta Ophthalmol Suppl. 1975;(125):11. doi: 10.1111/j.1755-3768.1975.tb01202.x. No abstract available.

Reference Type BACKGROUND
PMID: 184645 (View on PubMed)

Jakobiec FA, Coleman DJ, Chattock A, Smith M. Ultrasonically guided needle biopsy and cytologic diagnosis of solid intraocular tumors. Ophthalmology. 1979 Sep;86(9):1662-81. doi: 10.1016/s0161-6420(79)35349-0.

Reference Type BACKGROUND
PMID: 551354 (View on PubMed)

Caminal JM, Sanz S, Carreras M, Catala I, Arruga J, Roca G. Epibulbar seeding at the site of a transvitreal fine-needle aspiration biopsy. Arch Ophthalmol. 2006 Apr;124(4):587-9. doi: 10.1001/archopht.124.4.587. No abstract available.

Reference Type BACKGROUND
PMID: 16606890 (View on PubMed)

Glasgow BJ, Brown HH, Zargoza AM, Foos RY. Quantitation of tumor seeding from fine needle aspiration of ocular melanomas. Am J Ophthalmol. 1988 May 15;105(5):538-46. doi: 10.1016/0002-9394(88)90248-6.

Reference Type BACKGROUND
PMID: 3369520 (View on PubMed)

Karcioglu ZA, Gordon RA, Karcioglu GL. Tumor seeding in ocular fine needle aspiration biopsy. Ophthalmology. 1985 Dec;92(12):1763-7. doi: 10.1016/s0161-6420(85)34105-2.

Reference Type BACKGROUND
PMID: 4088631 (View on PubMed)

Engzell U, Esposti PL, Rubio C, Sigurdson A, Zajicek J. Investigation on tumour spread in connection with aspiration biopsy. Acta Radiol Ther Phys Biol. 1971 Aug;10(4):385-98. doi: 10.3109/02841867109130784. No abstract available.

Reference Type BACKGROUND
PMID: 4329702 (View on PubMed)

SNELL AC Jr. Heterotransplantation of tumors into various regions of the guinea-pig eye. Am J Ophthalmol. 1951 May;34(5 1):733-8. doi: 10.1016/0002-9394(51)92285-4. No abstract available.

Reference Type BACKGROUND
PMID: 14829489 (View on PubMed)

Shields JA, Shields CL, Ehya H, Eagle RC Jr, De Potter P. Fine-needle aspiration biopsy of suspected intraocular tumors. The 1992 Urwick Lecture. Ophthalmology. 1993 Nov;100(11):1677-84. doi: 10.1016/s0161-6420(93)31418-1.

Reference Type BACKGROUND
PMID: 8233394 (View on PubMed)

Schefler AC, Gologorsky D, Marr BP, Shields CL, Zeolite I, Abramson DH. Extraocular extension of uveal melanoma after fine-needle aspiration, vitrectomy, and open biopsy. JAMA Ophthalmol. 2013 Sep;131(9):1220-4. doi: 10.1001/jamaophthalmol.2013.2506.

Reference Type BACKGROUND
PMID: 24030334 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NBT-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

WT1 for the Detection of Minimal Residual Disease
NCT00179829 COMPLETED PHASE2/PHASE3
Biology Studies of Hematologic Cancers
NCT00923442 ENROLLING_BY_INVITATION
Huntsman Biopsy Study
NCT00615329 TERMINATED